Suppliers and packagers for zoledronic

zoledronic

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gland	ZOLEDRONIC	zoledronic acid	INJECTABLE;INTRAVENOUS	205749	ANDA	Gland Pharma Limited	68083-142-01	1 VIAL in 1 CARTON (68083-142-01) / 100 mL in 1 VIAL	2018-07-05

Zoledronic Acid: Key Supplier Landscape for a Critical Bisphosphonate

Last updated: February 19, 2026

Zoledronic acid, a potent bisphosphonate used to treat hypercalcemia of malignancy, bone metastases, and osteoporosis, relies on a complex supply chain for its active pharmaceutical ingredient (API) and key intermediates. This analysis identifies and characterizes the primary global suppliers.

Who Are the Leading API and Intermediate Suppliers for Zoledronic Acid?

The production of zoledronic acid involves several critical chemical synthesis steps, requiring specialized manufacturers for the API and its precursor intermediates. Key players are concentrated in regions with established fine chemical and pharmaceutical manufacturing capabilities, notably China and India.

Primary Zoledronic Acid API Manufacturers

Several companies globally produce zoledronic acid API, meeting stringent quality and regulatory standards for pharmaceutical use. These manufacturers often hold certifications such as GMP (Good Manufacturing Practice).

• Polpharma Pharmaceutical Works S.A. (Poland): A significant European producer of APIs, Polpharma is recognized for its expertise in complex molecules, including bisphosphonates. Their facility in Starogard Gdański is a primary manufacturing site.
• Hetero Drugs Ltd. (India): A major Indian pharmaceutical company, Hetero Drugs is a vertically integrated manufacturer with capabilities across API production. They are a substantial supplier to global markets.
• Lupin Ltd. (India): Another prominent Indian pharmaceutical firm, Lupin has a strong API manufacturing presence and is a known supplier of generics and their active ingredients, including zoledronic acid.
• Takeda Pharmaceutical Company (Japan): While Takeda is a major originator of zoledronic acid (as Zometa®), they also maintain internal API production capabilities and may supply to contract manufacturers or for their own formulations.
• Multiple Chinese Manufacturers: A number of Chinese API producers, often operating under the radar of broad public recognition, are significant suppliers. These include companies such as Hubei Biocause Pharmaceutical Co., Ltd. and Jiangxi Hesheng Pharmaceutical Co., Ltd. These companies are characterized by large-scale chemical synthesis operations and competitive pricing.

Key Intermediate Suppliers

The synthesis of zoledronic acid typically involves several key intermediates. The reliability and quality of these upstream components are crucial for API manufacturers.

• 1-Hydroxy-2-(imidazol-1-yl)ethane-1,1-diylbis(phosphonic acid) (Zoledronic Acid Intermediate): This is a direct precursor. Manufacturers of this intermediate often possess advanced phosphorus chemistry expertise. Companies like Innopharma Laboratories Pvt. Ltd. (India) have been identified as suppliers of this specific intermediate.
• Imidazoyl-2-ethane-1,1-diphosphonic acid: Another critical building block in the synthesis pathway. The production requires precise control over complex chemical reactions.
• Phosphorus Trichloride (PCl₃) and Phosphorus Oxychloride (POCl₃): These are fundamental phosphorus reagents used in bisphosphonate synthesis. Major global chemical manufacturers of industrial chemicals, such as BASF SE (Germany) or Lanxess AG (Germany), are indirect suppliers through their bulk chemical offerings.
• 2-aminoimidazole: A core heterocyclic component. Its synthesis requires specific organic chemistry capabilities.

What are the Regulatory and Quality Considerations for Zoledronic Acid Suppliers?

Suppliers of zoledronic acid API and key intermediates must adhere to rigorous regulatory frameworks to ensure product safety, efficacy, and quality.

Good Manufacturing Practice (GMP)

• FDA GMP: Manufacturers supplying to the United States market must comply with U.S. Food and Drug Administration (FDA) current Good Manufacturing Practice (cGMP) regulations. This includes site inspections, process validation, and robust quality management systems.
• EMA GMP: For the European market, compliance with European Medicines Agency (EMA) GMP guidelines is mandatory.
• WHO GMP: International harmonization through World Health Organization (WHO) GMP standards is also prevalent.
• Certifications: Facilities often seek certifications from various regulatory bodies, including ISO 9001 for quality management.

Drug Master Files (DMFs)

• US DMF: API manufacturers typically file a U.S. Drug Master File (DMF) with the FDA. This confidential document provides detailed information about the manufacturing process, facilities, and controls for the API.
• European CEP: In Europe, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) issued by the EDQM (European Directorate for the Quality of Medicines & HealthCare) serves a similar purpose, demonstrating compliance with European Pharmacopoeia standards.

Quality Control and Specifications

• Pharmacopoeial Standards: Suppliers must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
• Impurity Profiling: Rigorous analytical testing is required to identify and quantify impurities, including genotoxic impurities. Control strategies for these impurities are critical.
• Stability Studies: Manufacturers must conduct extensive stability studies to establish appropriate storage conditions and retest periods.

How Does Patent Protection Influence the Zoledronic Acid Supply Chain?

The patent landscape for zoledronic acid and its manufacturing processes significantly impacts market entry for generic manufacturers and influences supplier relationships.

Key Patents and Expiry Dates

The original compound patent for zoledronic acid has long expired. However, process patents and patents related to specific crystalline forms or formulations can still affect generic competition and API sourcing.

• Original Composition of Matter Patent: Expired (e.g., US4939178A filed in 1988, granted in 1990).
• Process Patents: Various patents cover specific synthetic routes and purification methods. The expiry of these process patents can open avenues for new manufacturers or allow existing ones to optimize their production. For example, patents related to specific polymorphic forms or improved synthetic yields are critical.
• Formulation Patents: Patents on specific formulations (e.g., injectable solutions) may extend market exclusivity for branded products, influencing the demand for API from generic manufacturers.

Impact on Generic Market Entry

• Freedom to Operate (FTO): Generic drug developers and API suppliers must conduct thorough FTO analyses to ensure their manufacturing processes and products do not infringe on existing valid patents.
• Generic Competition: As key process patents expire, more API manufacturers gain the ability to produce zoledronic acid, leading to increased competition and potentially lower API prices. This encourages diversification of the supplier base.
• Orphan Drug Status: Zoledronic acid is used for specific indications that may have had orphan drug designations, which can influence market exclusivity periods and patent enforcement strategies for the originator.

What are the Market Dynamics and Geographic Concentration of Suppliers?

The global supply of zoledronic acid API and intermediates is characterized by a significant concentration of manufacturers in Asia, coupled with specialized European producers.

Geographic Distribution

• China: Dominant in large-scale chemical synthesis and API production. Numerous companies operate here, offering competitive pricing.
• India: A strong hub for generic API manufacturing, with established quality systems and significant export volumes.
• Europe (Poland, Germany): Hosts high-quality API producers with strong regulatory compliance, often catering to Western markets where stringent quality and supply chain security are paramount.
• United States: While the US is a major consumer of zoledronic acid, domestic API manufacturing capacity for this specific molecule is less pronounced compared to Asia, though some contract manufacturing organizations (CMOs) may produce it.

Market Trends

• Consolidation: The API manufacturing sector is subject to ongoing consolidation, which can impact supplier availability and pricing.
• Supply Chain Resilience: Recent global events have heightened the focus on supply chain resilience, leading some pharmaceutical companies to diversify their supplier base and explore dual sourcing strategies.
• Cost Pressures: Generic drug markets are highly price-sensitive, creating continuous pressure on API manufacturers to optimize production costs while maintaining quality.
• Regulatory Scrutiny: Increased regulatory scrutiny on API sourcing and impurity control, particularly genotoxic impurities, requires suppliers to invest in advanced analytical capabilities and robust quality systems.

What are the Analytical and Quality Challenges in Zoledronic Acid Production?

Ensuring the consistent quality and purity of zoledronic acid API presents specific analytical and manufacturing challenges.

Impurity Control

• Related Substances: The synthesis pathway can generate various related substances and isomers. Identifying and controlling these through process optimization and purification is critical.
• Genotoxic Impurities: Certain reagents or by-products in the synthesis of complex molecules can be genotoxic. Detecting and controlling these at trace levels (parts per million or billion) requires sophisticated analytical techniques such as LC-MS/MS or GC-MS. For zoledronic acid, potential genotoxic impurities can arise from residual starting materials or degradation products.
• Residual Solvents: Strict limits are imposed on residual solvents used during synthesis and purification.

Polymorphism

• Crystalline Forms: Zoledronic acid can exist in different crystalline forms (polymorphs), which can affect solubility, bioavailability, and stability. Manufacturers must control the manufacturing process to consistently produce the desired polymorphic form.
• Characterization: Techniques like X-ray Powder Diffraction (XRPD), Differential Scanning Calorimetry (DSC), and Thermogravimetric Analysis (TGA) are used to characterize polymorphic forms.

Analytical Method Development and Validation

• Method Specificity: Analytical methods must be specific enough to accurately quantify zoledronic acid in the presence of related impurities and excipients.
• Sensitivity: High sensitivity is required for the detection of trace impurities, especially genotoxic ones.
• Method Validation: All analytical methods must be rigorously validated according to ICH (International Council for Harmonisation) guidelines.

Key Takeaways

• The global supply of zoledronic acid API is dominated by manufacturers in China and India, with established European producers also playing a significant role.
• Key intermediates for zoledronic acid synthesis are also largely sourced from Asian chemical manufacturers.
• Regulatory compliance, particularly GMP adherence and comprehensive impurity profiling, is paramount for all suppliers.
• Patent expiry on original composition of matter has enabled generic production, but process and formulation patents continue to shape market dynamics.
• Controlling related substances, genotoxic impurities, and polymorphic forms are critical quality challenges in zoledronic acid API manufacturing.

FAQs

What are the primary regulatory requirements for zoledronic acid API suppliers?

Suppliers must comply with Good Manufacturing Practice (GMP) standards set by regulatory bodies like the FDA and EMA. They must also maintain Drug Master Files (DMFs) or obtain Certificates of Suitability (CEPs) and adhere to pharmacopoeial specifications.

How can a pharmaceutical company ensure the quality and reliability of its zoledronic acid API supplier?

Companies should conduct thorough supplier audits, review quality agreements, assess regulatory compliance history, and implement robust incoming material testing protocols. Dual sourcing can also enhance supply chain reliability.

What is the typical lead time for sourcing zoledronic acid API from a new supplier?

Lead times can vary significantly based on the supplier's capacity, existing backorders, and the complexity of any necessary qualification or validation processes. It typically ranges from 3 to 9 months, including auditing and initial batch testing.

Are there specific environmental regulations that zoledronic acid API manufacturers must comply with?

Yes, manufacturers must comply with local and international environmental regulations regarding waste disposal, emissions control, and the use of hazardous chemicals during the synthesis process.

How does the pricing of zoledronic acid API fluctuate in the market?

Pricing is influenced by raw material costs, manufacturing scale, competitive landscape, regulatory compliance costs, and demand. Fluctuations can occur due to changes in these factors, including currency exchange rates and geopolitical events impacting raw material availability.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website] (Specific URL for DMF guidance is generally available but not to a single permanent page)

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from [EDQM website] (Specific URL for CEP information is generally available but not to a single permanent page)

[3] United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia. Retrieved from [USP website] (Access to specific monographs requires subscription)

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM website] (Access to specific monographs requires subscription)

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website] (Specific URLs for ICH guidelines are available)